Rafarm

Executive Summary

Rafarm is a Greek pharmaceutical company founded in 1976, specializing in the development and manufacturing of complex generic pharmaceuticals, with a strong focus on sterile injectables and ophthalmics. The company operates as an end-to-end Contract Development and Manufacturing Organization (CDMO) and also out-licenses its proprietary product dossiers globally. With state-of-the-art production capabilities and an innovation-driven, partnership-oriented business model, Rafarm positions itself as a key player in the European generics and CDMO market. Its emphasis on high-barrier-to-entry products such as sterile injectables offers differentiation and potential for stable revenue growth. As a private entity, Rafarm is not publicly traded, but its strategic partnerships and product pipeline are critical to its valuation.

Upcoming Catalysts (preview)

• Q4 2026FDA or EMA approval for a key complex generic injectable60% success
• Q2 2026Major CDMO contract win with a global pharmaceutical partner70% success
• Q3 2026Expansion of manufacturing capacity or new facility announcement50% success